Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
74
天
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study
作者
Ying Fan; Quchang Ouyang; Yongmei Yin; Lihua Song; Xiaojia Wang; Wei Li; Man Li; Xi Yan; Shusen Wang; Tao Sun; Yuee Teng; Xianjun Tang; Zhongsheng Tong; Zhengkui Sun; Junyou Ge; Xiaoping Jin; Yina Diao; Gesha Liu; Binghe Xu展开收起
作者单位
1. https://ror.org/02drdmm93grid.506261.60000 0001 0706 7839Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China; 2. https://ror.org/025020z88grid.410622.30000 0004 1758 2377Hunan Cancer Hospital,Changsha, China; 3. https://ror.org/04py1g812grid.412676.00000 0004 1799 0784Department of Oncology, The First Affiliated Hospital of Nanjing Medical University,Nanjing, China; 4. https://ror.org/059gcgy73grid.89957.3a0000 0000 9255 8984State Key Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University,Nanjing, China; 5. https://ror.org/01413r497grid.440144.10000 0004 1803 8437Shandong Cancer Hospital,Jinan, China; 6. https://ror.org/0144s0951grid.417397.f0000 0004 1808 0985Zhejiang Cancer Hospital,Hangzhou, China; 7. https://ror.org/034haf133grid.430605.40000 0004 1758 4110The First Hospital of Jilin University,Changchun, China; 8. https://ror.org/04c8eg608grid.411971.b0000 0000 9558 1426The Second Hospital of Dalian Medical University,Dalian, China; 9. https://ror.org/007mrxy13grid.412901.f0000 0004 1770 1022West China Hospital of Sichuan University,Chengdu, China; 10. https://ror.org/0400g8r85grid.488530.20000 0004 1803 6191Sun Yat-sen University Cancer Center,Guangzhou, China; 11. https://ror.org/05d659s21grid.459742.90000 0004 1798 5889Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute,Shenyang, China; 12. https://ror.org/04wjghj95grid.412636.4The First Hospital of China Medical University,Shenyang, China; 13. https://ror.org/023rhb549grid.190737.b0000 0001 0154 0904Chongqing University Cancer Hospital,Chongqing, China; 14. https://ror.org/0152hn881grid.411918.40000 0004 1798 6427Tianjin Medical University Cancer Institute & Hospital,Tianjin, China; 15. https://ror.org/00v8g0168grid.452533.60000 0004 1763 3891Jiangxi Cancer Hospital,Nanchang, China; 16. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd, Chengdu, China; 17. National Engineering Research Center of Targeted Biologics, Chengdu, China; 18. https://ror.org/02drdmm93grid.506261.60000 0001 0706 7839Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021 China展开收起
228
天
Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies
作者
Sarah Kießling; Jana Durackova; Alina Michler; Alva B. C. Geisen; Natalia Santana Acevedo; Thomas Haaf展开收起
作者单位
1. https://ror.org/00fbnyb24grid.8379.50000 0001 1958 8658Institute of Human Genetics, Julius Maximilians University,97074 Würzburg, Germany; 2. https://ror.org/01226dv09grid.411941.80000 0000 9194 7179Institute of Clinical Genetics and Genomic Medicine, University Clinics,97080 Würzburg, Germany展开收起
132
天
E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
作者
Hiroshi Ishiguro; Yasuo Miyoshi; Hiroyuki Yasojima; Junichiro Watanabe; Toshimi Takano; Akihiko Shimomura; Eriko Tokunaga; Toru Mukohara; Yasuto Naoi; Daiko Matsuoka; Shiori Okumura; Yohei Otake; Takuya Suzuki; Takao Takase; Taro Semba; Ziming Zhao; Kan Yonemori展开收起
作者单位
1. https://ror.org/03ftky336grid.412377.40000 0004 0372 168XBreast Oncology Service, Saitama Medical University International Medical Center,Hidaka, Japan; 2. https://ror.org/001yc7927grid.272264.70000 0000 9142 153XDepartment of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University,Nishinomiya, Japan; 3. https://ror.org/03ntccx93grid.416698.4Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital,Osaka, Japan; 4. https://ror.org/01692sz90grid.258269.20000 0004 1762 2738Department of Breast Oncology, Juntendo University Graduate School of Medicine,Tokyo, Japan; 5. https://ror.org/03md8p445grid.486756.e0000 0004 0443 165XBreast Medical Oncology Department, The Cancer Institute Hospital of JFCR,Tokyo, Japan; 6. https://ror.org/00r9w3j27grid.45203.300000 0004 0489 0290Department of Breast and Medical Oncology, National Center for Global Health and Medicine,Tokyo, Japan; 7. https://ror.org/022296476grid.415613.4Department of Breast Oncology, NHO Kyushu Cancer Center,Fukuoka, Japan; 8. https://ror.org/03rm3gk43grid.497282.2Department of Medical Oncology, National Cancer Center Hospital East,Kashiwa, Japan; 9. https://ror.org/028vxwa22grid.272458.e0000 0001 0667 4960Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine,Kyoto, Japan; 10. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Japan and Asia Clinical Development Department, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 11. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Clinical Research, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 12. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Japan and Asia Clinical Data Science, Clinical Research, Deep Human Biology Learning, Eisai Co., Ltd.,Tokyo, Japan; 13. https://ror.org/04vvh7p27grid.418765.90000 0004 1756 5390Molecular Profiling Department, Discovery Concept Validation Function, Deep Human Biology Learning, Eisai Co., Ltd.,Ibaraki, Japan; 14. https://ror.org/0469x1750grid.418767.b0000 0004 0599 8842Human Biology Integration Foundation, Deep Human Biology Learning, Eisai Inc.,Nutley, NJ USA; 15. https://ror.org/0025ww868grid.272242.30000 0001 2168 5385Department of Medical Oncology, National Cancer Center Hospital,Tokyo, Japan展开收起
157
天
Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate sacituzumab govitecan and TRAIL agonists in triple negative breast cancer
作者
Yonit A. Addissie; Yoshimi E. Greer; Jayakumar Nair; Stanley Lipkowitz展开收起
作者单位
1. https://ror.org/040gcmg81grid.48336.3a0000 0004 1936 8075Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute,Bethesda, MD USA展开收起
96
天
Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer
作者
Balazs Acs; Xingrong Liu; Leo Gkekos; Emelie Karlsson; Anna L. V. Johansson; Per Karlsson; Anne Andersson; Antonios Valachis; Irma Fredriksson; Theodoros Foukakis; Johan Hartman展开收起
作者单位
1. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital,Stockholm, Sweden; 2. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Oncology-Pathology, Karolinska Institutet,Stockholm, Sweden; 3. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,Stockholm, Sweden; 4. https://ror.org/01tm6cn81grid.8761.80000 0000 9919 9582Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy and Sahlgrenska University Hospitial, University of Gothenburg,Gothenburg, Sweden; 5. https://ror.org/05kb8h459grid.12650.300000 0001 1034 3451Department of Diagnostics and Interventions, Oncology, Umeå University,Umeå, Sweden; 6. https://ror.org/05kytsw45grid.15895.300000 0001 0738 8966Department of Oncology, Faculty of Medicine and Health, Örebro University,Örebro, Sweden; 7. https://ror.org/056d84691grid.4714.60000 0004 1937 0626Department of Molecular Medicine and Surgery, Karolinska Institutet,Stockholm, Sweden; 8. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705Department of Breast-, Endocrine Tumors and Sarcoma, Karolinska Cancer Comprehensive Center, Karolinska University Hospital,Stockholm, Sweden; 9. Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; 10. https://ror.org/00m8d6786grid.24381.3c0000 0000 9241 5705MedTechLabs, Karolinska University Hospital, BioClinicum,NKS J5:20, Solnavägen, 30, 171 64 Solna, Sweden展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天